|
Researchers at NTNU and Oxford have found a hormone
that may offer an effective treatment for type 2
diabetes. The incidence of diabetes, especially type
2 diabetes, has skyrocketed over the last few
decades, according to a report from the World Health
Organization. The report says that there were 108
million adults with diabetes in 1980, but by 2014,
that number had grown to 422 million.
“Many people who are morbidly obese also have type 2
diabetes,” says Magnus Kringstad Olsen, a PhD
candidate at the Department of Cancer Research and
Molecular Medicine at NTNU.
Bariartic surgery is the most effective form of
weight loss for the morbidly obese. Patients who
undergo the surgery also show great improvements in
their diabetes after surgery. Many scientists have
wondered why.
Researchers have long believed that the remisssion
in type 2 diabetes after bariatic surgery is due to
the increased production of GLP-1, an
appetite-reducing hormone, says Olsen.
Researchers at NTNU and Oxford have discovered that
another hormone called PYY has many of the
characteristics that cause this effect.
The finding offers the possibility that drugs could
be used to stimulate the production of the hormone
to treat type 2 diabetes.
Professor Duan Chen was head of the NTNU group that
undertook the study in cooperation with the Oxford
Centre for Diabetes, Endocrinology and Metabolism at
the University of Oxford.
See also
Mechanism of action of whole milk and its components
on glycemic control in healthy young men
Link...
For more information
Cell Reports
PYY-Dependent Restoration of Impaired Insulin and
Glucagon Secretion in Type 2 Diabetes following
Roux-En-Y Gastric Bypass Surgery.
Reshma D. Ramracheya, Laura J. McCulloch, Anne
Clark, David Wiggins, Helene Johannessen, Magnus
Kringstad Olsen, Xing Cai, Chun-Mei Zhao, Duan Chen,
Patrik Rorsman.
DOI:10.1016/j.celrep.2016.03.091
Link...
World Health Organization
Global Report on Diabetes 2016
Link...
Norwegian University of Science and Technology
Link...
SINTEF
Link...
MDN |